$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli

$dfli Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017432 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$19.27M	$434.00	$0.00
YoY Change
Cost Of Revenue	$15.18M	$14.05M	$12.81M
YoY Change	3.99%	9.68%
Gross Profit	$4.098M	$4.743M	$5.495M
YoY Change	-41.69%	-13.69%
Gross Profit Margin	21.26%	1092857.14%
Selling, General & Admin	$11.42M	$13.68M	$6.718M
YoY Change	71.09%	103.62%
% of Gross Profit	278.72%	288.4%	122.26%
Research & Development	$1.067M	$880.0K	$339.0K
YoY Change	24.21%	159.59%
% of Gross Profit	26.04%	18.55%	6.17%
Depreciation & Amortization	$296.0K	$297.0K	$192.0K
YoY Change	-23.91%	54.69%
% of Gross Profit	7.22%	6.26%	3.49%
Operating Expenses	$12.49M	$14.56M	$258.9K
YoY Change	2579.58%	5524.28%
Operating Profit	-$8.391M	-$9.816M	-$258.9K
YoY Change	1700.34%	3691.98%
Interest Expense	$4.113M	$3.815M	$1.263M
YoY Change	-446.5%	202.06%
% of Operating Profit
Other Income/Expense, Net	-$3.309M	$14.71M	$1.451M
YoY Change	3073.8%	913.86%
Pretax Income	-$11.70M	$4.892M	$1.192M
YoY Change	1951.44%	310.46%
Income Tax			-$527.0K
% Of Pretax Income			-44.22%
Net Earnings	-$11.70M	$4.892M	$1.192M
YoY Change	1951.43%	310.46%
Net Earnings / Revenue	-60.7%	1127188.94%
Basic Earnings Per Share	-$0.25	$0.11	$0.08
Diluted Earnings Per Share	-$0.25	$0.10	$0.08
COMMON SHARES
Basic Shares Outstanding	45.89M shares	45.79M shares	15.81M
Diluted Shares Outstanding	47.42M shares	48.46M shares	15.81M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.95M	$15.79M	$647.2K
YoY Change	9322.4%	2339.97%	788.01%
Cash & Equivalents	$32.95M	$15.79M	$647.2K
Short-Term Investments
Other Short-Term Assets	$239.0K	$396.0K	$296.1K
YoY Change	3.58%	33.75%
Inventory	$44.20M	$51.81M
Prepaid Expenses			$296.1K
Receivables	$2.172M	$2.969M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$84.23M	$75.02M	$943.3K
YoY Change	14410.9%	7852.84%	1194.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.79M	$11.29M
YoY Change	12.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$128.4M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$19.70M	$15.49M	$128.4M
YoY Change	-84.68%	-87.94%	166442.12%
TOTAL ASSETS
Total Short-Term Assets	$84.23M	$75.02M	$943.3K
Total Long-Term Assets	$19.70M	$15.49M	$128.4M
Total Assets	$103.9M	$90.51M	$129.4M
YoY Change	-19.55%	-30.04%	86153.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.99M	$18.82M	$42.35K
YoY Change	39507.69%	44347.59%
Accrued Expenses	$11.00M	$9.414M	$121.6K
YoY Change	6494.9%	7642.8%	12058.4%
Deferred Revenue	$152.0K	$418.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$22.37M	$20.70M
YoY Change	329.24%
Total Short-Term Liabilities	$53.64M	$50.48M	$213.9K
YoY Change	16809.09%	23497.35%	69.79%
LONG-TERM LIABILITIES
Long-Term Debt			$0.00
YoY Change
Other Long-Term Liabilities	$18.08M	$7.711M	$601.6K
YoY Change	1955.98%	1181.71%
Total Long-Term Liabilities	$18.08M	$7.711M	$601.6K
YoY Change	1955.98%	1181.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$53.64M	$50.48M	$213.9K
Total Long-Term Liabilities	$18.08M	$7.711M	$601.6K
Total Liabilities	$71.72M	$58.19M	$815.6K
YoY Change	5893.83%	7035.49%	547.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.94M	-$22.24M	$167.2K
YoY Change	8318.62%	-13404.66%
Common Stock	$6.000K	$5.000K	$317.00
YoY Change	1792.74%	1477.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.21M	$32.32M	$167.5K
YoY Change
Total Liabilities & Shareholders Equity	$103.9M	$90.51M	$129.4M
YoY Change	-19.55%	-30.04%	86153.69%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.70M	$4.892M	$1.192M
YoY Change	1951.43%	310.46%
Depreciation, Depletion And Amortization	$296.0K	$297.0K	$192.0K
YoY Change	-23.91%	54.69%
Cash From Operating Activities	-$1.801M	-$3.838M	-$152.6K
YoY Change	505.46%	2414.58%	97.92%
INVESTING ACTIVITIES
Capital Expenditures	$1.982M	$589.0K	$4.524M
YoY Change	-58.87%	-86.98%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.982M	-$589.0K	-$4.524M
YoY Change	-58.87%	-86.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.94M	$2.437M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-1.801M	-$3.838M	-152.6K
Cash From Investing Activities	-1.982M	-$589.0K	-$4.524M
Cash From Financing Activities	20.94M	$2.437M	0.000
Net Change In Cash	17.16M	-$1.990M	-152.6K
YoY Change	-5869.18%	1203.81%	-418.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.801M	-$3.838M	-$152.6K
Capital Expenditures	$1.982M	$589.0K	$4.524M
Free Cash Flow	-$3.783M	-$4.427M	-$4.677M
YoY Change	-26.06%	-5.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001847986
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable		usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q1	DFLI	Non Cash Receivable Of Options Exercised NonCashReceivableOfOptionsExercised		usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2022Q1	DFLI	Cashless Exercise Of Liability Classified Warrants CashlessExerciseOfLiabilityClassifiedWarrants		usd
CY2023Q1	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2022Q1	DFLI	Earnout Shares EarnoutShares		shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2022Q1	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue		usd
CY2022Q1	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40730
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	DRAGONFLY ENERGY HOLDINGS CORP.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1873463
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1190 Trademark Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	#108
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Reno
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89521
CY2023Q1	dei	City Area Code CityAreaCode	(775)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	622-3448
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45885513	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15791000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17781000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2969000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1444000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	51812000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	49846000	usd
CY2023Q1	DFLI	Prepaid Expense Other Than Inventory Current PrepaidExpenseOtherThanInventoryCurrent	1820000	usd
CY2022Q4	DFLI	Prepaid Expense Other Than Inventory Current PrepaidExpenseOtherThanInventoryCurrent	1624000	usd
CY2023Q1	us-gaap	Supplies Supplies	1703000	usd
CY2022Q4	us-gaap	Supplies Supplies	2002000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	525000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	525000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	396000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	267000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	75016000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	73489000	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	11147000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	10214000	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	275000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	275000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1717000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1709000	usd
CY2023Q1	DFLI	Vehicle Gross VehicleGross	33000	usd
CY2022Q4	DFLI	Vehicle Gross VehicleGross	195000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13172000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12393000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1884000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1633000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11288000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10760000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4205000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4513000	usd
CY2023Q1	us-gaap	Assets Assets	90509000	usd
CY2022Q4	us-gaap	Assets Assets	88762000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	18824000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13475000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8199000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6295000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	418000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	238000	usd
CY2023Q1	DFLI	Uncertain Tax Position Liability UncertainTaxPositionLiability	128000	usd
CY2022Q4	DFLI	Uncertain Tax Position Liability UncertainTaxPositionLiability	128000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1215000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	50483000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40566000	usd
CY2023Q1	DFLI	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	4141000	usd
CY2022Q4	DFLI	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	32831000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	361000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	492000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3209000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3541000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7711000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	36864000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	58194000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	77430000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45795502	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45795502	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43272728	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43272728	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54551000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38461000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22241000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27133000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32315000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11332000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90509000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88762000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18791000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18303000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14048000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12808000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	4743000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	5495000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	880000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	339000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9495000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3626000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4184000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3092000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14559000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7057000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9816000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1562000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3815000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1263000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-18523000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14708000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1263000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4892000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2825000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-527000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4892000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2298000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45104515	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36542944	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48455996	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36542944	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14061000	usd
CY2022Q1	DFLI	Stock Issued During Period Value Retroactive Application Of Recapitalizations StockIssuedDuringPeriodValueRetroactiveApplicationOfRecapitalizations	2000000	usd
CY2022Q1	DFLI	Stockholders Equity Adjusted Balance StockholdersEquityAdjustedBalance	16061000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2298000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	288000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14164000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14164000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11332000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11332000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4892000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4892000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	597000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	93000	usd
CY2023Q1	DFLI	Stock Issued During Period Value Exercise Of Public Warrants StockIssuedDuringPeriodValueExerciseOfPublicWarrants	747000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10167000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4487000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32315000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32315000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4892000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2298000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4487000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	288000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	219000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	613000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-18523000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-527000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1238000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	52000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	297000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	192000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-116000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-62000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1577000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1217000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1966000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5946000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	196000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	502000	usd
CY2023Q1	DFLI	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	-299000	usd
CY2022Q1	DFLI	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	-2425000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	129000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	637000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-308000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-274000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-11000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6465000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4119000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	180000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	293000	usd
CY2023Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-8730000	usd
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-8812000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3838000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11110000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	589000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4524000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-589000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4524000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	597000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	747000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	93000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	111000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2437000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1990000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15523000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17781000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28630000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15791000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13107000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2003	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	658	usd
CY2022Q1	DFLI	Non Cash Receivable Of Options Exercised NonCashReceivableOfOptionsExercised	2000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	352000	usd
CY2023Q1	DFLI	Cashless Exercise Of Liability Classified Warrants CashlessExerciseOfLiabilityClassifiedWarrants	10167000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3690955	shares
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_z1j7XAQGhDuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif; text-transform: uppercase"><b>NOTE 1 - <span id="xdx_826_zRnix3BUSf16">NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dragonfly Energy Holdings Corp. (“New Dragonfly” or the “Company”) sells lithium ion battery packs for use in a wide variety of applications. The Company sells to distributors under the Dragonfly Energy brand name, and sells direct to consumers under the trade name Battleborn Batteries. In addition, the Company develops technology for improved lithium ion battery manufacturing and assembly methods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 7, 2022, a merger transaction between Chardan NexTech Acquisition 2 Corporation (“CNTQ”), Dragonfly Energy Corp. (“Legacy Dragonfly”), and Bronco Merger Sub, Inc. (“Merger Sub”) was completed pursuant to which Merger Sub was merged with and into Legacy Dragonfly, with Legacy Dragonfly surviving the merger. As a result of the merger, Legacy Dragonfly became a wholly owned subsidiary of New Dragonfly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although New Dragonfly was the legal acquirer of Legacy Dragonfly in the merger, Legacy Dragonfly is deemed to be the accounting acquirer, and the historical financial statements of Legacy Dragonfly became the basis for the historical financial statements of New Dragonfly upon the closing of the merger. New Dragonfly together with its wholly owned subsidiary, Dragonfly Energy Corp., is referred to hereinafter as the “Company.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, the historical financial statements of Legacy Dragonfly became the historical financial statements of the Company upon the consummation of the merger. As a result, the financial statements included in this Quarterly Report reflect (i) the historical operating results of Legacy Dragonfly prior to the merger; (ii) the combined results of CNTQ and Legacy Dragonfly following the close of the merger; (iii) the assets and liabilities of Legacy Dragonfly at their historical cost and (iv) the Legacy Dragonfly’s equity structure for all periods presented, as affected by the recapitalization presentation after completion of the merger.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15791000	usd
CY2023Q1	DFLI	Working Capital WorkingCapital	24533000	usd
CY2023Q1	DFLI	Period Within Which Payment Is Due From Customers PeriodWithinWhichPaymentIsDueFromCustomers	30 – 60 days
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	116000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	90000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	297000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	192000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zwIInguOIMo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zdvUHy7OCtbl">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	418000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	238000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	211000	usd
CY2023Q1	us-gaap	Other Liabilities OtherLiabilities	211000	usd
CY2023Q1	us-gaap	Revenues Revenues	434	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18791000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18303000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18791000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18303000	usd
CY2023Q1	DFLI	Shipping And Handling Costs ShippingAndHandlingCosts	1007000	usd
CY2022Q1	DFLI	Shipping And Handling Costs ShippingAndHandlingCosts	1228000	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	400000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	328000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zakgCSfvOARa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zyzggZww4OX8">Concentrations</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables from <span id="xdx_90E_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20230101__20230331_zbtXtAe5iMq2" title="Number of customers">one</span> customer comprised approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zv8JM5Fsiluh" title="Concentration risk, percentage">50</span>% of accounts receivable as of March 31, 2023. Receivables from <span id="xdx_907_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20220101__20221231_zq81dKGmgLEh" title="Number of customers">three</span> customers comprised approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zlaBf7yBMkNe" title="Concentration risk, percentage">18</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_znzMtNJn8I5c" title="Concentration risk, percentage">10</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zkst5ZnN0OEf" title="Concentration risk, percentage">10</span>%, respectively, of accounts receivable as of December 31, 2022. There are no other significant accounts receivable concentration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales from <span id="xdx_905_ecustom--NumberOfVendors_pid_dc_uCustomer_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAynJ5pJgL11" title="Number of vendors">one</span> customer comprised approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zWvUejsSgwX4" title="Concentration risk, percentage">26</span>% of revenue for the three months ended March 31, 2023. There were no significant revenue concentrations for the three months ended March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payables to <span id="xdx_90E_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zaq5BlZQajog" title="Number of vendors">one</span> vendor comprised approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zYGGrdBYvFfe" title="Concentration risk, percentage">67</span>% of accounts payables as of March 31, 2023. Payables to <span id="xdx_902_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zF7s2KaHWKP" title="Number of vendors">one</span> vendor comprised approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zA9BOpCKcOWi" title="Concentration risk, percentage">61</span>% of accounts payables as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2023, <span id="xdx_903_ecustom--NumberOfVendors_pid_dc_uVendor_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zRsiyK8ACbI3" title="Number of vendors">two</span> vendors accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zlyLbQDP9KJi" title="Concentration risk, percentage">38</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zVHrRNxpkK8e" title="Concentration risk, percentage">10</span>%, respectively, of the Company’s total purchases. For the three months ended March 31, 2022, <span id="xdx_90F_ecustom--NumberOfVendors_pid_dc_uVendor_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zdeVuA8a4tU9" title="Number of vendors">one</span> vendor accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zgavPUxPMXb9" title="Concentration risk, percentage">34</span>% of the Company’s total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	DFLI	Number Of Customers NumberOfCustomers	1	customer
CY2022	DFLI	Number Of Customers NumberOfCustomers	3	customer
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	587000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	781000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	128000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	128000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	44310000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	42586000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7502000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7260000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	51812000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	49846000	usd
CY2022Q1	DFLI	Lessee Operating Lease Monthly Base Rent LesseeOperatingLeaseMonthlyBaseRent	230000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	23000	usd
CY2022Q1	DFLI	Lessee Operating Lease Estimated Monthly Property Taxes LesseeOperatingLeaseEstimatedMonthlyPropertyTaxes	21000	usd
CY2022Q1	DFLI	Lessee Operating Lease Percentage Of Escalation Of Monthly Base Rent LesseeOperatingLeasePercentageOfEscalationOfMonthlyBaseRent	0.03	pure
CY2022Q1	DFLI	Lessee Operating Lease Percentage Of Escalation Of Fix Operating Expense Costs LesseeOperatingLeasePercentageOfEscalationOfFixOperatingExpenseCosts	0.024	pure
CY2022Q1	DFLI	Lessee Operating Lease Term Of Due Of First Payment LesseeOperatingLeaseTermOfDueOfFirstPayment	P2Y
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4205000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4513000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1215000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3209000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3541000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4424000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4729000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1054000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1435000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1435000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	893000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4817000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	393000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4424000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	393000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	215000	usd
CY2023Q1	DFLI	Business Acquisition Equity Interest Issued Or Issuable Additional Number Of Shares BusinessAcquisitionEquityInterestIssuedOrIssuableAdditionalNumberOfShares	40000000	shares
CY2023Q1	DFLI	Audited Revenue AuditedRevenue	250000000	usd
CY2023Q1	DFLI	Audited Operating Income AuditedOperatingIncome	35000000	usd
CY2023Q1	DFLI	Liquidity Description LiquidityDescription	The Company shall not permit their Liquidity (determined on a consolidated basis) to be less than $10,000 as of the last day of each fiscal month (commencing with month ending December 31, 2022)
CY2023Q1	DFLI	Fixed Charge Coverage Ratio Description FixedChargeCoverageRatioDescription	The Fixed Charge Coverage Ratio is the ratio of consolidated EBITDA (less capital expenditures and certain other adjustments) to consolidated fixed charges, as defined in the agreement. If Liquidity is less than $15,000 as of the last day of any fiscal quarter (commencing with the quarter ending December 31, 2022), then the Company shall not permit the Fixed Charge Coverage Ratio for the trailing four quarterly periods ending on the last day of any such quarter to be less than 1.15 to 1.00
CY2023Q1	DFLI	Capital Expenditures Description CapitalExpendituresDescription	If consolidated EBITDA for the trailing twelve month period ending on the most recently completed fiscal quarter is less than $15,000, then the level of capital expenditures is limited
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	938000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3750000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	91775000	usd
CY2023Q1	DFLI	Long Term Debt Maturities Repayments Of Principal LongTermDebtMaturitiesRepaymentsOfPrincipal	96463000	usd
CY2023Q1	DFLI	Estimated Interest Paidinkind EstimatedInterestPaidinkind	-19033000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	77430000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56731000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20699000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	20699000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12266971	shares
CY2023Q1	DFLI	Earnout Shares EarnoutShares	40000000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4319309	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1205790	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	106113174	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	41418702	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4487000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	288000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023Q1	DFLI	Stock Issued During Period Value Exercise Of Public Warrants StockIssuedDuringPeriodValueExerciseOfPublicWarrants	747000	usd
CY2023Q1	DFLI	Stock Issued During Period Shares Exercise Of Public Warrants StockIssuedDuringPeriodSharesExerciseOfPublicWarrants	64971	shares
CY2022Q4	us-gaap	Share Price SharePrice	11.09
CY2022Q4	DFLI	Fair Value Of Warrant FairValueOfWarrant	11.89
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3731392	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3631002	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45795502	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36581910	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.98
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.38
CY2022Q1	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y6M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6550000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11584	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.44
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.17
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	48369	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.83
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3631002	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.00
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M14D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6377000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3642958	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.02
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.21
CY2023Q1	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35989000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	143607	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.82
CY2023Q1	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue	632000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	19164	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.27
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	3.71
CY2023Q1	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue	6000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36009	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.58
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.65
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	232000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3731392	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.20
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.30
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M13D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3800000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2029985	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.53
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y11M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3120000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3731392	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.20
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M13D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3800000	usd
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.182	pure
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4892000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2298000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45104515	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36542944	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4892000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2298000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45104515	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36542944	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3351481	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48455996	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36542944	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11034930	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3631002	shares
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-527000	usd

Files In Submission

Name	View Source	Status
dfli-20230331_cal.xml	Edgar Link	unprocessable
0001493152-23-017432-index-headers.html	Edgar Link	pending
0001493152-23-017432-index.html	Edgar Link	pending
0001493152-23-017432.txt	Edgar Link	pending
0001493152-23-017432-xbrl.zip	Edgar Link	pending
dfli-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
dfli-20230331_def.xml	Edgar Link	unprocessable
dfli-20230331_lab.xml	Edgar Link	unprocessable
dfli-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli

2023 Q2 Form 10-Q Financial Statement

#000149315223017432 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFLI Dragonfly Energy Holdings Corp. Stock $dfli

2023 Q2 Form 10-Q Financial Statement

#000149315223017432 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli